European Union · Question · QUESTION_WRITTEN
E-8-2016-004852
The role of off-patent innovation as regards access and sustainability of healthcare systems
Original
Introduced
15 June 2016
Last action
15 June 2016 · Written question
Status
QUESTION_WRITTEN
Sponsors
Giovanni LA VIA, Lieve WIERINCK
Subjects
Healthcare
Source updated
15 June 2016
Official titles
Authentic titles published by the source. The stored canonical title is not replaced.
Record
Official question E-8-2016-004852 from European Union at European Parliament. Dated 15 June 2016. Status: QUESTION_WRITTEN.
Timeline
15 June 2016
Written question
The role of off-patent innovation as regards access and sustainability of healthcare systems
Source: QUESTION_WRITTEN
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
15 official files
The role of off-patent innovation as regards access and sustainability of healthcare systems
QUESTION_WRITTEN · EN · 7 June 2018
The role of off-patent innovation as regards access and sustainability of healthcare systems
QUESTION_WRITTEN · EN · 7 June 2018
The role of off-patent innovation as regards access and sustainability of healthcare systems
QUESTION_WRITTEN · EN · 7 June 2018
The role of off-patent innovation as regards access and sustainability of healthcare systems
QUESTION_WRITTEN · EN · 7 June 2018
The role of off-patent innovation as regards access and sustainability of healthcare systems
QUESTION_WRITTEN · EN · 7 June 2018
Il ruolo dell'innovazione dei farmaci a brevetto scaduto per quanto riguarda l'accesso ai sistemi sanitari e la loro sostenibilità
QUESTION_WRITTEN · IT · 7 June 2018
Il ruolo dell'innovazione dei farmaci a brevetto scaduto per quanto riguarda l'accesso ai sistemi sanitari e la loro sostenibilità
QUESTION_WRITTEN · IT · 7 June 2018
Il ruolo dell'innovazione dei farmaci a brevetto scaduto per quanto riguarda l'accesso ai sistemi sanitari e la loro sostenibilità
QUESTION_WRITTEN · IT · 7 June 2018
Il ruolo dell'innovazione dei farmaci a brevetto scaduto per quanto riguarda l'accesso ai sistemi sanitari e la loro sostenibilità
QUESTION_WRITTEN · IT · 7 June 2018
Il ruolo dell'innovazione dei farmaci a brevetto scaduto per quanto riguarda l'accesso ai sistemi sanitari e la loro sostenibilità
QUESTION_WRITTEN · IT · 7 June 2018
De rol van de ontwikkeling van generieke geneesmiddelen voor de toegankelijkheid en betaalbaarheid van de gezondheidszorg
QUESTION_WRITTEN · NL · 7 June 2018
De rol van de ontwikkeling van generieke geneesmiddelen voor de toegankelijkheid en betaalbaarheid van de gezondheidszorg
QUESTION_WRITTEN · NL · 7 June 2018
De rol van de ontwikkeling van generieke geneesmiddelen voor de toegankelijkheid en betaalbaarheid van de gezondheidszorg
QUESTION_WRITTEN · NL · 7 June 2018
De rol van de ontwikkeling van generieke geneesmiddelen voor de toegankelijkheid en betaalbaarheid van de gezondheidszorg
QUESTION_WRITTEN · NL · 7 June 2018
De rol van de ontwikkeling van generieke geneesmiddelen voor de toegankelijkheid en betaalbaarheid van de gezondheidszorg
QUESTION_WRITTEN · NL · 7 June 2018
Sponsors
- Giovanni LA VIA · AUTHOR
- · COM · ADDRESSEE
- · EU_COMMISSION · ADDRESSEE
- Lieve WIERINCK · AUTHOR
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.europarl.europa.eu/doceo/document/E-8-2016-004852_EN.html
- Open data entity: https://data.europarl.europa.eu/api/v2/parliamentary-questions/E-8-2016-004852
- eu · E-8-2016-004852 · source updated 15 June 2016